conducted a study to establish a composite index for recent mortality in COPD patients, which will be helpful for physicians to make a decision to give palliative care in terminal COPD patients.
Results: A total of 558 patients were finally included in the analysis.
Thirty seven patients died within one year after enrolment. mMRC score and SaO 2 level were independent variables for predictors of one year mortality. The 11-point scale of this DO index showed that one year mortality in groups with scale 0-3, 4-7, 8-11 were 96.9%, 83.1%, and 37.5% respectively, and two year mortality in groups with scale 0-3, 4-7, 8-11 were 92.3%, 66.7%, and 25% respectively. Validation of this DO index in another cohort is still ongoing.
Conclusion:
Composite DO index with 11-point scale may be a useful tool for predicting recent mortality, which will be helpful for physicians to make a decision for palliative care in terminal COPD patients health is established, new aspect of it has been discovered in tissue and organs other than bones. Vitamin-D3 deficiency has been found in patients with various morbid disorders, such as cardiovascular diseases, autoimmune diseases, infectious diseases, Diabetes mellitus and malignancies including respiratory ailments.
This cross sectional study was designed to evaluate the status of fat soluble vitamin-D3 and its association with lung functions and exercise tolerance in stable COPD patients of Bangladesh. 
GlaxoSmithKline, China
Background and Aims: Inhaled long-acting muscarinic antagonist umeclidinium (UMEC) is an approved maintenance treatment for COPD in the US and EU. This is a regional phase III, randomized, double-blind, placebo-controlled, parallel group multicenter study with 24 weeks treatment period to evaluate the efficacy and safety of UMEC with placebo in patients with COPD of Asian ancestry.
Methods: Symptomatic COPD subjects were randomized to UMEC 62.5 mcg or placebo with 2:1 ratio. The primary efficacy endpoint was change from baseline in trough forced expiratory volume in 1 second (FEV1) on day 169; secondary end points were Transition Dyspnea Index (TDI) focal score at week 24 and weighted mean (WM) FEV1 over 0-6 h postdose on day 1. Safety was also assessed.
Results: 440 Asian subjects were enrolled from China and the Republic of Korea: 101 subjects were randomized to placebo and 205 to UMEC group and treated for 24 weeks. A clinically meaningful and statistical significant improvement in trough FEV1 was observed with UMEC compared with placebo at Day 169 (treatment difference 0.154 L, 95% confidence interval [CI] 0.113-0.194, P < 0.001). Statistically significant improvements in TDI score were observed for UMEC vs placebo (0.9, 95% CI 0.3-1.5, P = 0.004). The difference in weighted mean FEV1 over 0 to 6 h post dose on Day 1 was 125 mL (95% CI 0.103-0.147) in favour of UMEC, was also statistically significant (P<0.001). The incidence of adverse events was similar across groups.
Conclusion:
The efficacy of UMEC 62.5 mcg over placebo was demonstrated when administrated once-daily via the Ellipta inhaler over a 24-week treatment period in Asian subjects with COPD. The difference in lung function endpoints and TDI were statistically significantly in favour of UMEC over placebo. No new safety concerns were observed. 
